[1]
|
J. W. de Groot, T. P. Links, J. T. Plukker, et al., “Ret as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors,” Endocrine Reviews, Vol. 27, No. 5, 2006, pp. 535-560. doi:10.1210/er.2006-0017
|
[2]
|
P. J. Morrison and N. C. Nevin, “Multiple Endocrine Neoplasia Type 2B (Mucosal Neuroma Syndrome, Wagenmann-Froboese Syndrome),” Journal of Medical Genetics, Vol. 33, No. 9, 1996, pp. 779-782.
doi:10.1136/jmg.33.9.779
|
[3]
|
C. Eng, D. Clayton, I. Schuffenecker, et al., “The Relationship between Specific Ret Proto-Oncogene Mutations and Disease Phenotype in Multiple Endocrine Neoplasia Type 2. International Ret Mutation Consortium Analysis,” Journal of the American Medical Association, Vol. 276, No. 19, 1996, pp. 1575-1579.
doi:10.1001/jama.276.19.1575
|
[4]
|
R. L. Margraf, D. K. Crockett, P. M. Krautscheid, et al., “Multiple Endocrine Neoplasia Type 2 Ret Protooncogene Database: Repository of Men2-Associated Ret Sequence Variation and Reference for Genotype/Phenotype Correlations,” Human Mutation, Vol. 30, No. 4, 2009, pp. 548-556. doi:10.1002/humu.20928
|
[5]
|
M. Santoro, F. Carlomagno, A. Romano, et al., “Activation of Ret as a Dominant Transforming Gene by Germline Mutations of Men2a and Men2b,” Science, Vol. 267, No. 5196, 1995, pp. 381-383.
doi:10.1126/science.7824936
|
[6]
|
S. Chappuis-Flament, A. Pasini, G. De Vita, et al., “Dual Effect on the Ret Receptor of Men 2 Mutations Affecting Specific Extracytoplasmic Cysteines,” Oncogene, Vol. 17, No. 22, 1998, pp. 2851-2861. doi:10.1038/sj.onc.1202202
|
[7]
|
A. Z. Lai, T. S. Gujral and L. M. Mulligan, “Ret Signaling in Endocrine Tumors: Delving Deeper into Molecular Mechanisms,” Endocrine Pathology, Vol. 18, No. 2, 2007, pp. 57-67. doi:10.1007/s12022-007-0009-5
|
[8]
|
R. L. Margraf, R. Mao, W. E. Highsmith, et al., “Ret Proto-Oncogene Genotyping Using Unlabeled Probes, the Masking Technique, and Amplicon High-Resolution Melting Analysis,” Journal of Molecular Diagnostics, Vol. 9, No. 2, 2007, pp. 184-196.
doi:10.2353/jmoldx.2007.060091
|
[9]
|
L. Zhou, A. N. Myers, J. G. Vandersteen, et al., “Closed-Tube Genotyping with Unlabeled Oligonucleotide Probes and a Saturating DNA Dye,” Clinical Chemistry, Vol. 50, No. 8, 2004, pp. 1328-1335.
doi:10.1373/clinchem.2004.034322
|
[10]
|
M. Wiench, Z. Wygoda, E. Gubala, et al., “Estimation of Risk of Inherited Medullary Thyroid Carcinoma in Apparent Sporadic Patients,” Journal of Clinical Oncology, Vol. 19, No. 5, 2001, pp. 1374-1380.
|
[11]
|
D. P. Smith, C. Houghton and B. A. Ponder, “Germline Mutation of Ret Codon 883 in Two Cases of de Novo Men 2b,” Oncogene, Vol. 15, No. 10, 1997, pp. 1213-1217. doi:10.1038/sj.onc.1201481
|
[12]
|
K. Frank-Raue, S. Rondot, E. Schulze, et al., “Change in the Spectrum of Ret Mutations Diagnosed between 1994 and 2006,” Clinical Laboratory, Vol. 53, No. 5-6, 2007, pp. 273-282.
|
[13]
|
I. Berndt, M. Reuter, B. Saller, et al., “A New Hot Spot for Mutations in the Ret Protooncogene Causing Familial Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Type 2a,” Journal of Clinical Endocrinology & Metabolism, Vol. 83, No. 3, 1998, pp. 770-774.
doi:10.1210/jc.83.3.770
|
[14]
|
R. L. Margraf, J. D. Durtschi, J. E. Stephens, et al., “Determination of Ret Sequence Variation in an Men2 Unaffected Cohort Using Multiple-Sample Pooling and Next-Generation Sequencing,” Journal of Thyroid Research, Vol. 2012, 2012, Article ID: 318232.
doi:10.1155/2012/318232
|
[15]
|
K. Frank-Raue, L. A. Rybicki, Z. Erlic, et al., “Risk Profiles and Penetrance Estimations in Multiple Endocrine neoplasia Type 2a Caused by Germline Ret Mutations Located in Exon 10,” Human Mutation, Vol. 32, No. 1, 2010, pp. 51-58. doi:10.1002/humu.21385
|
[16]
|
R. T. Kloos, C. Eng, D. B. Evans, et al., “Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association,” Thyroid, Vol. 19, No. 6, 2009, pp. 565-612. doi:10.1089/thy.2008.0403
|